Update 22 November 2020: VivaZome features in lead article in International BioPharmaceutical Industry journal. “Exosome Therapeutics: Academic Curiosity or Commercial Reality” written by VivaZome CEO David Haylock and key academic collaborator Prof Andy Hill (La Trobe Uni).
Update 26 June 2020: VivaZome in the spotlight as Precinct Partner at La Trobe University
Update 20 June 2020: VivaZome features in “Inspire” – Research Australia’s Showcase for Health and Medical Research and Innovation.
Media Release 21 May 2020: VivaZome and Cytiva (formerly part of GE HealthCare Life Sciences) enter into an agreement on downstream technology for exosome purification
VivaZome – Cytiva Release May 2020 FINAL
Media Release 5 May 2020: VivaZome licenses University of Adelaide stem cell technology
VivaZome – University of Adelaide release 5 May 2020
Media Release 22 April 2020:VivaZome and ToolGen extend collaboration agreement based on successful proof-of-concept outcomes.
VivaZome – ToolGen release 22 April 2020
Media Release 8 November, 2019: Sienna and VivaZome to Evaluate EXO-NET(tm) for VivaZome’s Exosome-based Therapeutics
Vivazome – Sienna Collaboration release 8 Nov 2019
Media Release 30 October, 2019: David Haylock, PhD Appointed as Chief Executive Officer
VivaZome release 30 Oct 2019 David Haylock to CEO
Media Release 27 August 2019: Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
VivaZome – ToolGen release FINAL 27Aug2019
Media Release 14 August 2019: Dr David Haylock joins VivaZome Therapeutics as Chief Scientific Officer; Manufacturing development work begins at CSIRO.
VivaZome release Haylock – CSIRO 14 August 2019 FINAL
Media Release 18 December 2017: $2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy
